Neuroendocrine differentiation does not have independent prognostic value in conservatively treated prostate cancer (original) (raw)
Bonkhoff H, Stein U, Remberger K (1993) Androgen receptor status in endocrine-paracrine cell types of the normal, hyperplastic, and neoplastic human prostate. Virchows Arch A Pathol Anat Histopathol 423:291–294 ArticlePubMedCAS Google Scholar
Krijnen JL, Janssen PJ, Ruizeveld de Winter JA, van Krimpen H, Schroder FH, van der Kwast TH (1993) Do neuroendocrine cells in human prostate cancer express androgen receptor? Histochemistry 100:393–398 ArticlePubMedCAS Google Scholar
Ather MH, Abbas F, Faruqui N, Israr M, Pervez S (2008) Correlation of three immunohistochemically detected markers of neuroendocrine differentiation with clinical predictors of disease progression in prostate cancer. BMC Urol 8:21 ArticlePubMed Google Scholar
Isshiki S, Akakura K, Komiya A, Suzuki H, Kamiya N, Ito H (2002) Chromogranin a concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer. J Urol 167:512–515 ArticlePubMedCAS Google Scholar
Di Sant' Agnese PA (1992) Neuroendocr Differ Carcinoma Prostate Cancer 70:254–268 Google Scholar
Albertsen PC, Hanley JA, Fine J (2005) 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293:2095–2101 ArticlePubMedCAS Google Scholar
Yokomizo A, Murai M, Baba S, Ogawa O, Tsukamoto T, Niwakawa M, Tobisu K, Kinukawa N, Naito S (2006) Percentage of positive biopsy cores, preoperative prostate-specific antigen (PSA) level, pT and Gleason score as predictors of PSA recurrence after radical prostatectomy: a multi-institutional outcome study in Japan. BJU Int 98:549–553 ArticlePubMedCAS Google Scholar
Cuzick J, Fisher G, Kattan MW, Berney D, Oliver T, Foster CS, Moller H, Reuter V, Fearn P, Eastham J, Scardino P (2006) Long-term outcome among men with conservatively treated localised prostate cancer. Br J Cancer 95:1186–1194 ArticlePubMedCAS Google Scholar
Tewari A, Johnson CC, Divine G, Crawford ED, Gamito EJ, Demers R, Menon M (2004) Long-term survival probability in men with clinically localized prostate cancer: a case-control, propensity modeling study stratified by race, age, treatment and comorbidities. J Urol 171:1513–1519 ArticlePubMed Google Scholar
Cox ME, Deeble PD, Lakhani S, Parsons SJ (1999) Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression. Cancer Res 59:3821–3830 PubMedCAS Google Scholar
Deng X, Liu H, Huang J, Cheng L, Keller ET, Parsons SJ, Hu CD (2008) Ionizing radiation induces prostate cancer neuroendocrine differentiation through interplay of CREB and ATF2: implications for disease progression. Cancer Res 68:9663–9670 ArticlePubMedCAS Google Scholar
Diaz M, Abdul M, Hoosein N (1998) Modulation of neuroendocrine differentiation in prostate cancer by interleukin-1 and -2. Prostate Suppl 8:32–36 ArticlePubMedCAS Google Scholar
Huss WJ, Gregory CW, Smith GJ (2004) Neuroendocrine cell differentiation in the CWR22 human prostate cancer xenograft: association with tumor cell proliferation prior to recurrence. Prostate 60:91–97 ArticlePubMed Google Scholar
Jongsma J, Oomen MH, Noordzij MA, Van Weerden WM, Martens GJ, van der Kwast TH, Schroder FH, van Steenbrugge GJ (2002) Different profiles of neuroendocrine cell differentiation evolve in the PC-310 human prostate cancer model during long-term androgen deprivation. Prostate 50:203–215 ArticlePubMedCAS Google Scholar
Nelson EC, Cambio AJ, Yang JC, Ok JH, Lara PN Jr, Evans CP (2007) Clinical implications of neuroendocrine differentiation in prostate cancer. Prostate Cancer Prostatic Dis 10:6–14 ArticlePubMedCAS Google Scholar
Quiros-Gonzalez I, Sainz RM, Hevia D, Mayo JC MnSOD drives neuroendocrine differentiation, androgen independence, and cell survival in prostate cancer cells. Free Radic Biol Med 50:525–536
Wu C, Huang J (2007) Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway is essential for neuroendocrine differentiation of prostate cancer. J Biol Chem 282:3571–3583 ArticlePubMedCAS Google Scholar
Zhang XQ, Kondrikov D, Yuan TC, Lin FF, Hansen J, Lin MF (2003) Receptor protein tyrosine phosphatase alpha signaling is involved in androgen depletion-induced neuroendocrine differentiation of androgen-sensitive LNCaP human prostate cancer cells. Oncogene 22:6704–6716 ArticlePubMedCAS Google Scholar
Abrahamsson PA, Cockett AT, di Sant'Agnese PA (1998) Prognostic significance of neuroendocrine differentiation in clinically localized prostatic carcinoma. Prostate Suppl 8:37–42 ArticlePubMedCAS Google Scholar
Krijnen JL, Bogdanowicz JF, Seldenrijk CA, Mulder PG, van der Kwast TH (1997) The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy. J Urol 158:171–174 ArticlePubMedCAS Google Scholar
Autorino R, Di Lorenzo G, D'Armiento FP, Mignogna C, Cindolo L, De Sio M, Perdona S, De Fortuna E, Salzano L, De Placido S, D'Armiento M (2005) Neuroendocrine differentiation after neoadjuvant hormonal treatment in prostate cancer. Minerva Urol Nefrol 57:319–324 PubMedCAS Google Scholar
Sciarra A, Mariotti G, Gentile V, Voria G, Pastore A, Monti S, Di Silverio F (2003) Neuroendocrine differentiation in human prostate tissue: is it detectable and treatable? BJU Int 91:438–445 ArticlePubMedCAS Google Scholar
Gunia S, Albrecht K, Koch S, Herrmann T, Ecke T, Loy V, Linke J, Siegsmund M, May M (2008) Ki67 staining index and neuroendocrine differentiation aggravate adverse prognostic parameters in prostate cancer and are characterized by negligible inter-observer variability. World J Urol 26:243–250 ArticlePubMed Google Scholar
Berney DM, Fisher G, Kattan MW, Oliver RT, Moller H, Fearn P, Eastham J, Scardino P, Cuzick J, Reuter VE, Foster CS (2007) Major shifts in the treatment and prognosis of prostate cancer due to changes in pathological diagnosis and grading. BJU Int 100:1240–1244 ArticlePubMed Google Scholar
Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL (2005) The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 29:1228–1242 ArticlePubMed Google Scholar
Turbat-Herrera EA, Herrera GA, Gore I, Lott RL, Grizzle WE, Bonnin JM (1988) Neuroendocrine differentiation in prostatic carcinomas. A retrospective autopsy study. Arch Pathol Lab Med 112:1100–1105 PubMedCAS Google Scholar
Bonkhoff H (2001) Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status. Ann Oncol 12(Suppl 2):S141–S144 ArticlePubMed Google Scholar
Xing N, Qian J, Bostwick D, Bergstralh E, Young CY (2001) Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin. Prostate 48:7–15 ArticlePubMedCAS Google Scholar
Jongsma J, Oomen MH, Noordzij MA, Van Weerden WM, Martens GJ, van der Kwast TH, Schroder FH, van Steenbrugge GJ (2000) Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation. Cancer Res 60:741–748 PubMedCAS Google Scholar
Allen FJ, Van Velden DJ, Heyns CF (1995) Are neuroendocrine cells of practical value as an independent prognostic parameter in prostate cancer? Br J Urol 75:751–754 ArticlePubMedCAS Google Scholar
Tan MO, Karaoglan U, Celik B, Ataoglu O, Biri H, Bozkirli I (1999) Prostate cancer and neuroendocrine differentiation. Int Urol Nephrol 31:75–82 ArticlePubMedCAS Google Scholar
Cerovic SJ, Brajuskovic GR, Vukotic Maletic VD, Micic SR (2004) Neuroendocrine differentiation in prostate cancer. Vojnosanit Pregl 61:513–518 ArticlePubMed Google Scholar
Cindolo L, Cantile M, Franco R, Chiodini P, Schiavo G, Forte I, Zlobec I, Salzano L, Botti G, Gidaro S, Terracciano L, Cillo C Parallel determination of neuroD1, chromogranin-A, KI67 and androgen receptor expression in surgically treated prostate cancers. Int Braz J Urol 37:57–66
Falkmer S, Askensten U, Grimelius L, Abrahamsson PA (1990) Cytochemical markers and DNA content of neuroendocrine cells in carcinoma of the prostate gland during tumour progression. Acta Histochem Suppl 38:127–132 PubMedCAS Google Scholar
Cohen RJ, Glezerson G, Haffejee Z (1991) Neuro-endocrine cells—a new prognostic parameter in prostate cancer. Br J Urol 68:258–262 ArticlePubMedCAS Google Scholar
Collado B, Gutierrez-Canas I, Rodriguez-Henche N, Prieto JC, Carmena MJ (2004) Vasoactive intestinal peptide increases vascular endothelial growth factor expression and neuroendocrine differentiation in human prostate cancer LNCaP cells. Regul Pept 119:69–75 ArticlePubMedCAS Google Scholar
Humez S, Monet M, Legrand G, Lepage G, Delcourt P, Prevarskaya N (2006) Epidermal growth factor-induced neuroendocrine differentiation and apoptotic resistance of androgen-independent human prostate cancer cells. Endocr Relat Cancer 13:181–195 ArticlePubMedCAS Google Scholar
di Sant'Agnese PA (2001) Neuroendocrine differentiation in prostatic carcinoma: an update on recent developments. Ann Oncol 12(Suppl 2):S135–S140 ArticlePubMed Google Scholar
Ahlgren G, Pedersen K, Lundberg S, Aus G, Hugosson J, Abrahamsson PA (2000) Regressive changes and neuroendocrine differentiation in prostate cancer after neoadjuvant hormonal treatment. Prostate 42:274–279 ArticlePubMedCAS Google Scholar
Hirano D, Okada Y, Minei S, Takimoto Y, Nemoto N (2004) Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol 45:586–592, discussion 592 ArticlePubMedCAS Google Scholar